骨密度作为骨质疏松试验替代终点的探讨
[Correspondence] Bone mineral density as a surrogate endpoint in osteoporosis trials
RSS 订阅 · The Lancet Diabetes and Endocrinology
本文是对Ian R Reid观点的回应，讨论SABRE协作报告的治疗相关全髋骨密度变化与骨折风险降低之间的关联。
要点
- 治疗相关全髋骨密度变化与骨折风险降低的关联可能受低疗效药物试验影响
- 提示骨密度作为替代终点需谨慎解读
核心结论
- Reid认为SABRE协作报告的骨密度变化与骨折风险降低的关联主要由低疗效药物驱动
研究设计与样本
- 本文为对Ian R Reid观点文章的回应，属于信件类
主要发现
- SABRE协作报告了治疗相关全髋骨密度变化与骨折风险降低的关联
- 该关联在低疗效药物试验中更为明显
临床怎么用
- 临床解读骨密度替代终点时应考虑药物疗效强度
- 避免仅依据骨密度变化推断抗骨折疗效
局限性
- 原文未提供具体研究样本量或统计细节
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
Ian R Reid argues in his Viewpoint1 that the association reported by the SABRE collaboration between treatment-related changes in total hip bone mineral density (BMD) and fracture-risk reduction is largely driven by trials of less effective therapies, and that, if attention were restricted to agents producing greater than 3·2% increases in hip BMD, there would be no convincing association between BMD change and anti-fracture efficacy.
来源：The Lancet Diabetes and Endocrinology，查看原文。版权归原作者所有。
引用
- The Lancet Diabetes and Endocrinology：[Correspondence] Bone mineral density as a surrogate endpoint in osteoporosis trials
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。